



Microbial production of 3-hydroxypropionic acid

Jensen, Niels Bjerg; Borodina, Irina; Chen, Yun; Maury, Jerome; Kildegaard, Kanchana Rueksomtawin; Förster, Jochen; Nielsen, Jens

Publication date:
2014

Document Version
Publisher's PDF, also known as Version of record

[Link back to DTU Orbit](#)

Citation (APA):
Jensen, N. B., Borodina, I., Chen, Y., Maury, J., Kildegaard, K. R., Förster, J., & Nielsen, J. (2014). Microbial production of 3-hydroxypropionic acid. (Patent No. WO2014198831).

General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



WIPO | PCT



(10) International Publication Number
WO 2014/198831 A1

(43) International Publication Date
18 December 2014 (18.12.2014)

(51) International Patent Classification:

C12N 9/02 (2006.01) C12P 7/42 (2006.01)
C12N 9/00 (2006.01) C12P 7/52 (2006.01)

(21) International Application Number:

PCT/EP2014/062246

(22) International Filing Date:

12 June 2014 (12.06.2014)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

13172149.0 14 June 2013 (14.06.2013) EP

(71) Applicant: TECHNICAL UNIVERSITY OF DENMARK [DK/DK]; Anker Engelundsvej 1, Building 101A, DK-2800 Kgs. Lyngby (DK).

(72) Inventors: JENSEN, Niels, Bjerg; Technical University of Denmark, Anker Engelundsvej 1, Building 101A, DK-2800 Kgs. Lyngby (DK). BORODINA, Irina; Technical University of Denmark, Anker Engelundsvej 1, Building 101A, DK-2800 Kgs. Lyngby (DK). CHEN, Yun; Technical University of Denmark, Anker Engelundsvej 1, Building 101A, DK-2800 Kgs. Lyngby (DK). MAURY, Jerome; Technical University of Denmark, Anker Engelundsvej 1, Building 101A, DK-2800 Kgs. Lyngby (DK). KILDEGAARD, Kanchana, Rueksomtawin; Technical University of Denmark, Anker Engelundsvej 1, Building 101A, DK-2800 Kgs. Lyngby (DK). FÖRSTER, Jochen; Technical University of Denmark, Anker Engelundsvej 1, Building 101A, DK-2800 Kgs. Lyngby (DK). NIELSEN, Jens; Technical University of Denmark,

Anker Engelundsvej 1, Building 101A, DK-2800 Kgs. Lyngby (DK).

(74) Agent: SMART, Peter; Beck Greener, Fulwood House, 12 Fulwood Place, London London WC1V 6HR (GB).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

(54) Title: MICROBIAL PRODUCTION OF 3-HYDROXYPROPIONIC ACID

(57) Abstract: A yeast cell having a reduced level of activity of NAD dependent glyceraldehyde-3-phosphate dehydrogenase (GAPDH) has at least one exogenous gene encoding NADP dependent GAPDH and/or has up-regulation of at least one endogenous gene expressing NADP dependent GAPDH, wherein combined expression of the enzymes NADP dependent GAPDH, PDC, ALD, ACS, ACC* and MCR in said host cell increases metabolic flux towards 3-HP via malonyl-CoA compared to an otherwise similar yeast cell lacking said genetic modification.



WO 2014/198831 A1

Microbial production of 3-hydroxypropionic acid**Technical Field**

The present invention relates to a recombinant yeast cells
5 and their use in the production of 3-hydroxypropionic acid
(3-HP).

Background Art

For more than a century, fossil fuels have been the primary
feedstock for the chemical industries. However, new
10 discoveries of fossil fuel deposits are diminishing whilst
demand for fossil fuel based chemicals are ever increasing,
and soon the supply of fossil fuels will be outweighed by the
demand. In an attempt to address this issue a large amount
of effort has gone into developing novel biotechnological
15 strategies for producing chemical feedstock from renewable
sources (e.g. sugars). In 2004 the Department of Energy in
the USA identified a list of 12 target feedstock chemicals to
be produced through biotechnological routes. 3-hydroxy
propionic acid (3-HP) has been chosen as one of the 12
20 feedstock chemicals as it can serve as a platform for the
development of a range of 3-carbon petrochemical
intermediates, and in particular it can be dehydrated to form
acrylic acid. More than 1 billion kilograms of acrylic acid
are produced annually as it is the monomeric building block
25 for polymeric acrylates which can be used in a wide range of
consumer products, e.g. personal care products, adhesives,
coatings and paints, and the annual total market size is over
USD100 billion. One particularly important application of 3-
HP is for the production of superabsorbent polymers (SAP),
30 which constitute a significant part of baby diapers and
incontinence products. It is evidently desirable to develop
a more sustainable way of producing acrylic acid, hence this

is why a significant amount of research continues towards the development of a biotechnological method of producing 3-HP, the acrylic acid precursor.

Conventional biological processes for producing 3-HP are performed by a complicated metabolic pathway. Therefore, it is difficult to control the process effectively, resulting in low production yield and productivity. For this reason it is necessary to design a 3-HP production pathway which controls the quantity of biochemical precursors in the cytosol such that the flux towards late stage biochemical intermediates in said 3-HP production pathway is favoured and alternative biological pathways are disfavoured.

EP 2505656 discloses a method of producing 3-HP using a malonic semialdehyde reducing pathway, wherein the process utilises an NADPH dependent malonyl-CoA reductase which may be derived from *C. aurantiacus* and an NADP/NADPH dependent GAPDH variant to resolve a redox imbalance within the metabolic process. The maximum reported yield of 3-HP was approximately 1.3 g/L.

Rathnasingh et al. (J. Biotechnol. 2012) discloses a method of producing 3-HP using *Escherichia coli* cells, wherein said cells overexpress MCR from *C. aurantiacus* and ACC in the malonyl-CoA pathway. The maximum reported yield of 3-HP was 2.14 mmol/L (0.19 g/L).

WO 2008/080124 discloses a method of producing butanol using modified yeast, wherein said method produces increased quantities of cytosolic acetyl-CoA by overexpressing PDC1 and ALD6 which may be derived from *S. cerevisiae* and ACS which may be derived from *S. enterica*. This method does not utilise the malonyl-CoA pathway.

WO 2007/024718 discloses a method of producing isoprenoid compounds using genetically modified host cells, wherein said cells are modified to produce increased levels of acetyl-CoA by increasing ALD and ACS activity. This method does not
5 utilise the malonyl-CoA pathway.

In *S. cerevisiae*, acetyl-CoA carboxylase is tightly regulated at the transcriptional, translational and post-translational levels (Shirra, M.K. et al, 2001; Nielsen, J. 2009). At the level of the protein, Snf1 kinase is the major kinase which
10 phosphorylates and inactivates ACC1 in vivo (Shirra, M.K. et al, 2001). WO 2012/017083 discloses a method of producing wax esters using modified yeast, wherein the quantity of cytosolic acetyl-CoA is increased through increasing the activity of ACC1 by mutating ACC1 at dephosphorylation sites
15 such that it is no longer inactivated by Snf1.

Description of the Invention

The present invention relates to a recombinant yeast cell which produces high supernatant concentrations (up to 10 g/L) of 3-HP by increasing the flux towards cytosolic malonyl-CoA, which is reduced to 3-HP by malonyl-CoA reductase (MCR). The
20 recombinant yeast cell overexpresses pyruvate decarboxylase (PDC), aldehyde dehydrogenase (ALD), Acetyl-CoA synthase (ACS), and a mutated Acetyl-CoA Carboxylase (ACC*) (the enzyme is mutated at two dephosphorylation sites to prevent
25 inactivation by Snf1) which increases the conversion of pyruvate to malonyl-CoA. MCR derived from *Chloroflexus aurantiacus* reduces malonyl-CoA to 3-HP using NADPH as a cofactor. In order to resolve the resulting redox imbalance within the metabolic process the endogenous NAD dependent
30 glyceraldehyde-3-phosphate dehydrogenase (GAPDH) is replaced with with an NADP dependent GAPDH variant.

None of the above cited art discloses the specific combination of the features of the herein described invention. Furthermore, the recombinant yeast of present invention produces 3-HP in substantially greater yields than
5 the cited art.

In a first aspect the present invention relates to a yeast cell for use in producing 3-hydroxypropionic acid (3-HP), wherein said yeast cell incorporates genetic modification such that said cell expresses the enzymes:

- 10 - Pyruvate decarboxylase (PDC)
- Aldehyde dehydrogenase (ALD)
- Acetyl-CoA synthase (ACS)
- Acetyl-CoA carboxylase (ACC*) mutated in at least one dephosphorylation site to prevent inactivation by Snf1
- 15 - Malonyl-CoA reductase (MCR),

said cell has a reduced level of activity of NAD dependent glyceraldehyde-3-phosphate dehydrogenase (GAPDH), suitably by virtue of deletion, attenuation, disruption, down-regulation, or mutation of one or more genes expressing NAD dependent
20 GAPDH and has at least one exogenous gene encoding NADP dependent GAPDH and/or has up-regulation of at least one endogenous gene expressing NADP dependent GAPDH. It has been found that combined expression of the enzymes NADP dependent GAPDH, PDC, ALD, ACS, ACC* and MCR in said host cell
25 increases metabolic flux towards 3-HP via malonyl-CoA compared to an otherwise similar yeast cell lacking said genetic modification.

In a preferred embodiment of the invention the recombinant yeast strain comprises one or more exogenous nucleic acid
30 molecules encoding at least one of PDC, ALD, ACS, ACC* and/or MCR. Preferably, said nucleic acid molecule is expressed

from multiple integrations of said nucleic acid molecule in the host cell genome. Such a multiply integrated nucleic acid molecule may encode, for example, MCR.

The nucleic acid molecule encoding PDC may be derived from
5 *Saccharomyces cerevisiae*. 'Derived from' is used herein to specify the species from which the original genetic material encoding the specified enzyme originated.

The nucleic acid molecule encoding ALD may be derived from *Saccharomyces cerevisiae*.

10 The nucleic acid molecule encoding ACS may be derived from *Salmonella enterica*.

The ACC* enzyme may be mutated in at least two dephosphorylation positions in the enzyme. In a preferred embodiment, the ACC* enzyme is mutated at amino acid
15 positions Ser659 and Ser1157. Suitably Ser659 and Ser1157 are replaced by amino acids comprising side chains which are incapable of being phosphorylated, preferably Ala, Val, Leu, Ile, Pro, Phe, Trp and/or Met. The nucleic acid molecule encoding the non-mutated version of the ACC* enzyme may be
20 derived from *Saccharomyces cerevisiae*.

The nucleic acid molecule encoding MCR may be derived from *Chloroflexus aurantiacus*.

The nucleic acid molecule encoding NADP dependent GAPDH may be derived from *Clostridium acetobutylicum*, *Kluyveromyces*
25 *lactis* or *Bacillus subtilis*.

In another aspect, the present invention relates to a method for producing 3-HP, said method comprising culturing yeast cells as described herein under conditions such that 3-HP is produced.

In a preferred embodiment of the invention, the yeast cells are cultured on a medium comprising at least one carbon substrate, wherein said carbon substrate may be glucose or galactose.

- 5 Preferably, culturing said yeast cells on a medium comprising at least one carbon substrate produces a supernatant concentration of at least 5 g/L 3-HP, more preferably said yeast cells produce a supernatant concentration of at least 6 g/L 3-HP, more preferably said yeast cells produce a
10 supernatant concentration of at least 7 g/L 3-HP, more preferably said yeast cells produce a supernatant concentration of at least 8 g/L 3-HP, and most preferably said yeast cells produce a supernatant concentration of at least 9 g/L 3-HP.
- 15 In another preferred embodiment of the invention, said method further comprises isolating 3-HP produced by said recombinant yeast strain.

Figures

Figure 1: Bar chart comparing yeast cells transformed with
20 ACC comprising zero, one or two mutations at dephosphorylation sites.

Figure 2: Bar chart comparing the supernatant concentration of 3-HP produced by yeast cells transformed with a multicopy vector, a single integrative vector and a multiple
25 integrative vector.

Figure 3: Bar chart comparing the supernatant concentration of 3-HP produced by yeast cells overexpressing ACS, ALD6 and/or PDC1 in both DELFT and FIT media.

Figure 4: Bar chart comparing the supernatant concentration of 3-HP produced by yeast cells with increased pool of available NADPH and those with no increased pool of available NADPH.

- 5 Figure 5: Bar chart demonstrating the effect of replacing the coding sequence of endogenous NAD dependent GAPDH with NADP dependent GAPDH on supernatant concentration of 3-HP in both DELFT and FIT media.

Figure 6: Bar chart comparing the supernatant concentration
10 of 3-HP produced by yeast cells with improved NADPH supply in DELFT and FIT media.

Figure 7: Graph showing the supernatant concentration of 3-HP, glucose, glycerol, acetate and ethanol vs time in an N and C limited fed batch fermentation of highest producing
15 yeast strain ST687

Figure 8: Graph showing the supernatant concentration of 3-HP, glucose, glycerol, acetate and ethanol vs time in a C limited fed batch fermentation of the highest producing yeast strain ST687

Examples**Table 1. Oligonucleotide sequences**

Oligo name	Oligo sequence 5' --> 3'	Seq ID NO
ACC1m_fw	CGTGCGAUTCATTTCAAAGTCTTCAACAATTT	Seq ID NO 11
ACC1m_rv	AGTGCAGGUAAAAACAATGAGCGAAGAAAGCTTA	Seq ID NO 12
CaMCR_fw_NEW	ATCTGTCAUAAAAACAATGAGTGGTACAGGTAG	Seq ID NO 13
CaMCR_rv_NEW	CACGCGAUTCAGACTGTAATGGCTCTACCTC	Seq ID NO 14
PTEF1_fw	ACCTGCACUTTGTAAATTAAAACTTAG	Seq ID NO 15

PPGK1_rv	ATGACAGAUTTGTTTTATATTGTTG	Seq ID NO 16
ACC1-WT-UP	ATTTGGCGCCGCTTTAGTTTCTACCATGAGCGAAG	Seq ID NO 17
ACC1-WT-DOWN	GGCGAGCTCGCAAGTTTATTTCAAAAGTCTT	Seq ID NO 18
F-1-DOWNz	CATATGACAAATCTGAAACAGCAACAGCCCCTGTTTCATACC	Seq ID NO 19
F-2-UP	GGTATGAACAGGGCTGTGCTGTTTCAGATTGTGCATATG	Seq ID NO 20
F-3-DOWN	ATGGCAATCAAAAAGACCACCATCAGCTAGTTGACGCAGTA	Seq ID NO 21
F-4-UP	TACTGCGTCAACTAGCTGATGGTGGTCTTTTGATTGCCAT	Seq ID NO 22

ACSse_U1_fw	AGTGCAGGUAAAAACAATGTCAAAACACAC	Seq ID NO 23
ACSse_U1_rv	CGTGCGAUTCATGATGGCATAGCAATAG	Seq ID NO 24
ald6_U2_fw	ATCTGTCAUAAAAACAATGACTAAGCTACACTTTTGACAC	Seq ID NO 25
ald6_U2_rv	CACGCGAUTCACAACTTAATTCTGACAGCTTTTAC	Seq ID NO 26
pdc1_U1longer_fw	AGTGCAGGUAAAAACAATGTCTGAAATTACTTTGGGTAATATTG	Seq ID NO 27
pdc1_U1longer_rv	CGTGCGAUTCATTGCTTAGCGTTGGTAGCAGCAGTC	Seq ID NO 28
PTEF1_rv	CACGCGAUGCACACACCATAGCTTC	Seq ID NO 29

Table 2. Primers and templates used to generate gene fragments for USER cloning and yeast transformation by PCR

Fragment name	Gene	Fw primer	Rv primer	Template DNA
ACC**<-	ACC1 Ser659Ala, Ser1157Ala from <i>S. cerevisiae</i>	ACC1m_fw	ACC1m_rv	pAD
->CaMCR	Malonyl-CoA reductase from <i>Chloroflexus aurantiacus</i>	CaMCR_fw_NEW	CaMCR_rv_NEW	pYC6
<-ScPTEF1- ScPPGK1->	Fused promoters of tef1 and pgk1 genes from <i>S. cerevisiae</i>	PTEF1_fw	PPGK1_rv	plasmid pSP-GM1
ACC-pTEFpPGK- CaMCR	ACC1**<-ScPTEF1-ScPPGK1-> >CaMCR	ACC1m_fw	CaMCR_rv_NEW	P298
ACSse<-	Acetyl-CoA synthetase from <i>Salmonella enterica</i>	ACSse_U1_fw	ACSse_U1_rv	P324
ScALD6->	Acetaldehyde dehydrogenase 6 from <i>S. cerevisiae</i>	ald6_U2_fw	ald6_U2_rv	<i>S. cerevisiae</i> gDNA

ScPDC1<-	Pyruvate decarboxylase isozyme 1 from <i>S. cerevisiae</i>	pdcl_U1longer_fw	pdcl_U1longer_rv	<i>S. cerevisiae</i> gDNA
<-ScPTEF1	TEF1 promoter from <i>S. cerevisiae</i>	PTEF1_fw	PTEF1_rv	<i>S. cerevisiae</i> gDNA

Table 3. Plasmids

Plasmid name	Parent plasmid	Selection marker	Gene 1	Promoter	Gene 2
P298	p054 pESC-URA-USER	URA3	ACC1**<- (Seq ID NO 1)	<-ScPTEF1-ScPPGK1-> (Seq ID NO 3)	->CaMCR (Seq ID NO 2)
P343	P0255 pX-2-1oxP-KlURA3	KlURA3	ACC1**<- (Seq ID NO 1)	<-ScPTEF1-ScPPGK1-> (Seq ID NO 3)	->CaMCR (Seq ID NO 2)
P376	P322	KlURA3	ACC1**<-	<-ScPTEF1-ScPPGK1->	->CaMCR

			(Seq ID NO 1)	(Seq ID NO 3)	(Seq ID NO 2)
P474	P376	K1URA3	ACC1**<- (Seq ID NO 1)	<-ScPTEF1-ScPPGK1-> (Seq ID NO 3)	->CaMCR (Seq ID NO 2)
P380	p257 (pX-3- K1LEU2)	K1LEU2	ACSse<- (Seq ID NO 4)	<-ScPTEF1-ScPPGK1-> (Seq ID NO 3)	ScALD6-> (Seq ID NO 5)
P382	p258 (pX-4- LoxP-SpHis5)	SpHis5	ScPDC1<- (Seq ID NO 6)	<-ScPTEF1 (Seq ID NO 7)	

3 **Table 4. Yeast strains**

Strain	Parent strain	Genotype
CEN.PK102-5B		mata,ura3,his3,leu2
CEN.PK102-5D		mata, ura3
tdh3-null	CEN.PK102-5B	mata,ura3,his3,leu2,tdh3::LoxP
tdh1::CaGAPDH, tdh3	tdh3-null	mata,ura3,his3,leu2,tdh1::CaGAPDH- LoxP,tdh3::LoxP

tdh2::CaGAPDH, tdh3	tdh3-null	mata, ura3, his3, leu2, tdh2::CaGAPDH-LoxP, tdh3::LoxP
tdh1+2::CaGAPDH, tdh3	tdh2::CaGAPDH, tdh3	mata, ura3, his3, leu2, tdh1::CaGAPDH-LoxP, tdh2::CaGAPDH-LoxP, tdh3::LoxP
tdh3::CaGAPDH	CEN. PK102-5B	mata, ura3, his3, leu2, tdh3::CaGAPDH-LoxP
tdh1+3::CaGAPDH	tdh3::CaGAPDH	mata, ura3, his3, leu2, tdh1::CaGAPDH-LoxP, tdh3::CaGAPDH-LoxP
tdh2+3::CaGAPDH	tdh3::CaGAPDH	mata, ura3, his3, leu2, tdh2::CaGAPDH-LoxP, tdh3::CaGAPDH-LoxP
tdh1+2+3::CaGAPDH	tdh2+3::CaGAPDH	mata, ura3, his3, leu2, tdh1::CaGAPDH-LoxP, tdh2::CaGAPDH-LoxP, tdh3::CaGAPDH-LoxP

Example 1. Cloning of over-expression targets into expression plasmids.

All plasmids listed in table 3 were generated by USER cloning using PCR generated gene fragments, which were amplified
5 according to table 2. The typical USER reaction was as follows: 1 µl of linearized and nicked parent plasmid was mixed with 1 µl of promoter fragment, 2 µl of gene fragment, 0.5 µl Taq polymerase buffer, 0.5 µl USER enzyme (NEB). The mix was incubated at 37°C for 25 min, at 25°C for 25 min and
10 transformed into chemically competent *E. coli* DH5alpha. The clones with correct inserts were identified by colony PCR and the plasmids were isolated from overnight *E. coli* cultures and confirmed by sequencing.

The expression plasmids were transformed into *S. cerevisiae*
15 cells using the lithium acetate transformation protocol. The cells were selected on synthetic complete (SC) agar medium without uracil, histidine and leucine.

Example 2. ACC1 Engineering acetyl-CoA carboxylase for improving the production of 3-hydroxypropionic acid**

20 Ser659 and Ser1157 of ACC1 were identified as two putative phosphorylation sites according to the phosphorylation recognition motif (Hyd-X-Arg-XX-Ser-XXX-Hyd) for yeast Snf1 (Dale, S. et al, 1995). One of which, Ser1157 was verified by a phosphoproteome study (Ficarro, S. et al, 2002). Ser659 has
25 not been reported through experimental data so far. Therefore, we have constructed mutated ACC1 with either one or two assumed phosphorylation sites.

The endogenous ACC1 gene (wild-type) encoding acetyl-CoA carboxylase was amplified from genomic DNA of CEN.PK.113-5D
30 by PCR with Phusion high-fidelity polymerase. The primers are

listed in Table 1. The single mutation ACC1^{Ser1157Ala} and double mutation ACC1^{Ser659Ala, Ser1157Ala} were introduced by oligonucleotide primers. Three versions of ACC1 were digested with NotI and SacI, and then ligated into the corresponding sites of pSP-GM2 (Chen et al., 2012), resulting in plasmid pAW (containing wild-type ACC1), pAS (containing single mutated ACC1) and pAD (containing double mutated ACC1), respectively.

For re-constructing the pathway for 3-HP production, the gene CaMCR encoding malonyl-CoA reductase from *Chloroflexus aurantiacus* was codon optimized for expression in yeast and synthesized by GenScript (Piscataway, NJ, USA). CaMCR was cloned into pIYC04 (Chen et al., 2013) using the BamHI and XhoI cloning sites downstream of the TEF1 promoter, resulting in plasmid pYC6. To evaluate the effect of engineered ACC1 on 3-HP production, plasmids combinations pSP-GM2 / pYC6, pAW / pYC6, pAS / pYC6 and pAD / pYC6 were transformed into CEN.PK 113-11C to construct yeast recombinant strain HPY15 to HPY18, respectively.

For the cultivation of yeast recombinant strains, 20 ml cultures in 100 ml unbaffled cotton-stopped flasks were inoculated with an amount of pre-culture that resulted in a final optical density of 0.02 at 600 nm (OD₆₀₀). The strains were grown at 30 °C with 180 r.p.m. orbital shaking in defined minimal medium with 20 g l⁻¹ glucose as described before (Chen et al., 2013). Samples were taken periodically to measure the cell mass, concentration of 3-HP, residual glucose and other metabolites.

The results are shown in figure 1. Overexpression of wild-type ACC1 HPY16 increased 3-HP production by 60%, compared to the reference strain HPY15. Overexpression of mutated ACC1 by

blocking the phosphorylation sites, HPY17 and HPY18, further enhanced the production of 3-HP. Double mutated ACC1^{Ser659Ala}, Ser1157Ala HPY18 gave the highest improvement, around three-fold, relevant to that of the reference strain.

5 **Example 3. Production of 3HP in *S. cerevisiae* by over-expression of CaMCR and ACC1** from multiple integration plasmids**

CEN.PK102-5D was transformed with either episomal multicopy plasmid p298, or single integrative plasmid p343, or multiple
10 integration plasmid p376. All three plasmids tested harboured ACC1** and CaMCR. Four single transformants for each plasmid tested were inoculated in 0.5 ml SC ura- in a 96-deep well microtiter plate with air-penetrable lid (EnzyScreen). The plates were incubated at 30°C with 250 rpm agitation at 5 cm
15 orbit cast overnight. 50 µl of the overnight cultures were used to inoculate 0.5 ml Delft medium (Delft medium described in WO 2011/147818) in a 96-deep well plate and 0.5 ml FIT Fed-batch-media (M2P labs). Fermentation was carried out for 72 hours at the same conditions as above.

20 At the end of the cultivation the OD₆₀₀ was measured. 10 µl of the sample was mixed with 190 µl water and absorbance was measured at 600 nm wave length in a spectrophotometer (BioTek).

The culture broth was spun down and the supernatant analyzed
25 for 3-hydroxypropionic acid concentration using enzymatic assay, which was performed as follows: 20 µl of standards (3HP at concentrations from 0.03 to 1 g/L in Delft medium) and samples were added to a 96-well flat bottom transparent plate (Greiner). 180 µl of mix (14.8 ml water, 2 ml buffer
30 (1 mM Tris, 25 mM MgCl₂, pH 8.8), 1 ml NADP⁺ solution (50

mg/ml), and 0.2 ml purified YdfG enzyme in PBS buffer (1500 µg/ml)) was added per well using a multichannel pipette. The start absorbance at 340 nm was measured and the plate was sealed and incubated at 30°C for 1.5 hours. After incubation the absorbance at 340 nm was measured again. The difference between the end and the start values corrected for the background were in linear correlation with 3HP concentrations. The concentration of 3HP in each sample was calculated from the standard curve.

Expression of ACC1** and CaMCR from the multiple integration plasmid p376 led to a 5 times improvement of 3HP production in the best clone, when compared to a *S. cerevisiae* strain bearing a single integrative vector with the same genes (figure 2).

Example 4. Improving 3HP production in *S. cerevisiae* by increasing the precursor supply towards Acetyl-CoA

Strains harbouring either p380-ALD6-ACS or p380-ALD6-ACS in combination with p382-PDC1 were transformed with p474-CaMCR-ACC1**. A minimum of 6 clones were picked, fermented and tested for 3HP production by enzymatic assay as in example 2 (figure 3). The best producer of strains having p380-ALD6-ACS in combination with p474-CaMCR-ACC1** gave up to 1.5 fold higher 3HP titer than the wild type (WT) strain with p474-CaMCR-ACC1**, and strains with all three plasmids combined gave up to 2.5 times more than the WT background in both DELFT and FIT media.

Example 5. Effect of Increasing the pool of available NADPH on the production of 3-hydroxypropionic acid

The effect of increasing NADPH supply on the production of 3-hydroxypropionic acid was tested. The gapN gene from

Streptococcus mutants, which encodes non-phosphorylating NADP-dependent glyceraldehyde-3-phosphate dehydrogenase, was codon optimized and synthesized by GeneScript (Piscataway, NJ, USA). The gene gapN was cloned into pIYC04 (Chen et al., 2013) using the restriction sites NotI and SacI, resulting in plasmid pJC2. Plasmids pJC2 and pYC1 were transformed into CEN.PK 113-11C, forming the recombinant yeast strain HPY09. It was found that the over-expression of gapN alone resulted in a final titer of 122 mg l⁻¹ 3-HP, which is a 30% improvement compared to the reference strain (figure 4).

Example 6. Construction of strain with improved NADPH supply

An elevated level of NADPH was achieved by overexpression of an NADP dependent glyceraldehyde-3-phosphate dehydrogenase gene from either *Clostridium acetobutylicum*, CaGAPDH (Seq ID NO 08), *Kluyveromyces lactis*, KlGAPDH (Seq ID NO 9), or *Bacillus subtilis*, BsGapB (Seq ID NO 10). The NADP dependent GAPDH was expressed in yeast strains, where one, two or three of the endogenous NAD dependent glyceraldehyde-3-phosphate dehydrogenase genes TDH1-3 were deleted and/or exchanged with the CDS of GAPDH. By exchanging the CDS we aimed to ensure that the introduced GAPDH had the same expression profile as the endogenous NAD dependent GAPDH. Additionally, any potential futile cycling between the endogenous GAPDH and the introduced GAPDH was avoided by removing or lowering the level of endogenous GAPDH activity. Eight different combinations were made according to Table 4. Each of those eight strains and a WT strain were all transformed with p380-ALD6-ACS in combination with p382-PDC1 and p474-CaMCR-ACC1**. A minimum of 12 clones for each strain were tested for 3HP production as in example 2 (figure 5). In both media tested, there was a significant increase in 3HP yield for the strains

where TDH3 was replaced with CaGAPDH. However, there was no further effect when this exchange was combined with any of the other CDS exchanges. The three best producers for the WT and the *tdh3::CaGAPDH* strains were analyzed further by HPLC (figure 6). The 'WT' strains gave 1.46 ± 0.14 g/l and 3.31 ± 0.34 g/l 3HP in DELFT and FIT, respectively. The 'tdh3::CaGAPDH' strains gave 2.01 ± 0.01 g/l and 5.10 ± 0.22 g/l 3HP in DELFT and FIT, respectively. Furthermore, the ratio between 3HP formed and glycerol formed was higher for the *tdh3::CaGAPDH* strains in both media tested.

The best producer among the *tdh3::CaGAPDH* strains was named ST687 and was used in future fermentation experiments.

Example 7. Fermentations of high producing strain (ST687)

Strain ST687 was fermented under two different fermentation regimes; 1, N and C limited fed batch, and 2, C limited fed batch.

	N and C limited fed batch	C limited fed batch
Parameter	Value	Value
Reactor number	A1, A3, B2	A1, A2, A3
Organism	<i>S. cerevisiae</i>	<i>S. cerevisiae</i>
Strain	ST687	ST687

Batch medium	Mix per reactor: 20 ml (NH ₄) ₂ SO ₄ (100 g/L) , 25 ml KH ₂ PO ₄ (120 g/L) , 10 ml MgSO ₄ , 7H ₂ O (50 g/L), 1 ml trace metals, 0.2 ml antifoam, add water to 500 ml. Separately autoclave 110 g dextrose in 500 ml water, add 100 ml of this glucose solution to reactor after autoclavation. Also add 1 ml vitamins.	Mix per reactor: 75 ml (NH ₄) ₂ SO ₄ (100 g/L) , 25 ml KH ₂ PO ₄ (120 g/L) , 10 ml MgSO ₄ , 7H ₂ O (50 g/L), 2 ml trace metals, 0.2 ml antifoam, add water to 500 ml. Separately autoclave 110 g dextrose in 500 ml water, add 40 ml of this glucose solution to reactor after autoclavation. Also add 1 ml vitamins.
Feed medium	Mix per feed bottle: 0.5 L of 200 g/L glucose solution. Add about 100 ml (20 g) before inoculation to start the batch phase, then add the rest during the fed-batch phase.	Mix per feed bottle: 225 ml (NH ₄) ₂ SO ₄ (100 g/L) , 75 ml KH ₂ PO ₄ (120 g/L) , 30 ml MgSO ₄ , 7H ₂ O (50 g/L), 6 ml trace metals, 0.3 ml antifoam. This will make a total of 336 ml. Add the remaining glucose solution (160 ml) to the feed bottle after autoclavation. Also add 3 ml vitamins.
Temperature	30 °C	30 °C
pH	5	5
pH control	with 2M NaOH	with 2M NaOH
DO	not controlled	controlled at >20% by stirring speed and aeration

Working volume	batch with 0.5L, then fill up to 1 L during fed-batch	batch with 0.5L, then fill up to 1 L during fed-batch
Agitation	800 rpm	800 rpm (variable in the fed-batch phase)
Aeration	1 vvm (1 L/min)	1 vvm (1 L/min) (variable in the fed-batch phase)
Aeration gas	Air	Air
Fermentation length	70 hours	120 hours
Sampling frequency	2-3 times a day	2 times a day

The inoculum was prepared as follows. A stock tube of ST/687 was inoculated into 50 ml SC-ura-his-leu and grown overnight at 30°C. 400 ml fresh medium is added and divided into 3

5 flasks, 150 ml in each and grown overnight at 30°C. The cultures from overnight shake flasks is combined to obtain a total of about 450 ml, which then is poured into 6x50ml Falcon tubes. Tubes are spun 4,000xg for 2 min and supernatant is discarded. The rest of the overnight culture
 10 is added to the 6 tubes (about 25 ml/tube), resuspended, and pooled into 2 tubes into one to end up with 3 tubes. Inoculate 1 tube per reactor.

Each sample was analyzed by HPLC as in example 4. The results are summarized in table below and in figures 7 and 8.

	N and C limited	C limited
Titers (3-HP)	9.5 g/L	9.83 \pm 0.43 g/L
Prod. Rate in fed batch phase	0.20 g/L/h	0.09 \pm 0.01 g/L/h
Specific yield, g/g DW	1.01 g/g DW	0.69 \pm 0.05 g/g DW
Overall yield, % C-mol/C-mol glucose	18 %	13 \pm 1 %

Both fermentations involving the best 3-HP producing yeast strain ST687 produced supernatant concentrations of >9 g/L 3-HP. This is a significant increase over the supernatant concentrations disclosed in the prior art.

5

References

- Chen, Y., Partow, S., Scalcinati, G., Siewers, V., Nielsen, J. Enhancing the copy number of episomal plasmids in
5 *Saccharomyces cerevisiae* for improved protein production. *FEMS Yeast Res.* **12**, 598-607 (2012).
- Chen, Y., Daviet, L., Schalk, M., Siewers, V., Nielsen, J. Establishing a platform cell factory through engineering of yeast acetyl-CoA metabolism. *Metab Eng.* **15**, 48-54 (2013).
- 10 Dale, S., Wilson, W.A., Edelman, A.M. & Hardie, D.G. Similar substrate recognition motifs for mammalian AMP-activated protein kinase, higher plant HMG-CoA reductase kinase-A, yeast SNF1, and mammalian calmodulin-dependent protein kinase I. *FEBS Letters* **361**, 191-195 (1995).
- 15 Ficarro, S. et al. Phosphoproteome analysis by mass spectrometry and its application to *Saccharomyces cerevisiae*. *Nat Biotechnol* **20**, 301-305 (2002).
- Nielsen, J. Systems biology of lipid metabolism: From yeast to human. *FEBS Letters* **583**, 3905-3913 (2009).
- 20 Rathnasingh, C., Raj, S. M., Lee, Y., Catherine, C., Ashok, S., Park, S., J. Production of 3-hydroxypropionic acid via malonyl-CoA pathway using recombinant *Escherichia coli* strains. *J. Biotechnol.*, 633-640 (2012).
- Shirra, M.K. et al. Inhibition of Acetyl Coenzyme A
25 Carboxylase Activity Restores Expression of the INO1 Gene in a snf1 Mutant Strain of *Saccharomyces cerevisiae*. *Mol. Cell. Biol.* **21**, 5710-5722 (2001).

In this specification, unless expressly otherwise indicated, the word 'or' is used in the sense of an operator that returns a true value when either or both of the stated conditions is met, as opposed to the operator 'exclusive or' which requires that only one of the conditions is met. The word 'comprising' is used in the sense of 'including' rather than in to mean 'consisting of'. All prior teachings acknowledged above are hereby incorporated by reference. No acknowledgement of any prior published document herein should be taken to be an admission or representation that the teaching thereof was common general knowledge in Australia or elsewhere at the date hereof.

The invention may be summarised according to the following clauses:

1. A yeast cell for use in producing 3-hydroxypropionic acid (3-HP), wherein said yeast cell incorporates genetic modification such that said cell expresses the enzymes:

- Pyruvate decarboxylase (PDC)
- Aldehyde dehydrogenase (ALD)
- Acetyl-CoA synthase (ACS)
- Acetyl-CoA carboxylase (ACC*) mutated in at least one dephosphorylation site to prevent inactivation by Snf1
- Malonyl-CoA reductase (MCR),

said cell has a reduced level of activity of NAD dependent glyceraldehyde-3-phosphate dehydrogenase (GAPDH) by virtue of deletion, attenuation, disruption, down-regulation, or mutation of one or more genes expressing NAD dependent GAPDH and has at least one exogenous gene encoding NADP dependent

GAPDH and/or has up-regulation of at least one endogenous gene expressing NADP dependent GAPDH, and

wherein combined expression of the enzymes NADP dependent GAPDH, PDC, ALD, ACS, ACC* and MCR in said host cell

5 increases metabolic flux towards 3-HP via malonyl-CoA compared to an otherwise similar yeast cell lacking said genetic modification.

2. A yeast cell as defined in clause 1, comprising one or more exogenous nucleic acid molecules encoding at least one
10 of PDC, ALD, ACS, ACC* and/or MCR.

3. A yeast cell as defined in clause 2, wherein a said nucleic acid molecule is expressed from multiple integrations of said nucleic acid molecule in the host cell genome.

4. A yeast cell as defined in clause 2, wherein a nucleic
15 acid molecule encoding PDC is derived from *Saccharomyces cerevisiae*.

5. A yeast cell as defined in clause 2, wherein the nucleic acid molecule encoding ALD is derived from *Saccharomyces cerevisiae*.

20 6. A yeast cell as defined in clause 2, wherein a nucleic acid molecule encoding ACS is derived from *Salmonella enterica*.

7. A yeast cell as defined in clause 2, wherein a ACC* enzyme is mutated in at least two dephosphorylation positions
25 in the enzyme.

8. A yeast cell as defined in clause 7, wherein the ACC* enzyme is mutated at amino acid positions Ser659 and Ser1157, wherein Ser659 and Ser1157 are replaced by amino acids

comprising side chains which are incapable of being phosphorylated.

9. A yeast cell as defined in clause 8, wherein said amino acids comprising side chains which are incapable of being
5 phosphorylated are Ala, Val, Leu, Ile, Pro, Phe, Trp, Met.

10. A yeast cell as defined in clause 8, wherein the nucleic acid molecule encoding the non-mutated version of the ACC* enzyme is derived from *Saccharomyces cerevisiae*.

10 11. A yeast cell as defined in clause 2, wherein a nucleic acid molecule encoding MCR is derived from *Chloroflexus aurantiacus*.

12. A yeast cell as defined in clause 1, wherein a nucleic acid molecule encoding NADP dependent GAPDH is derived from *Clostridium acetobutylicum*, *Kluyveromyces lactis* or *Bacillus*
15 *subtilis*.

13. A method for producing 3-HP, said method comprising culturing yeast cells as claimed in any of the preceding claims under conditions such that 3-HP is produced.

14. A method as defined in clause 13, wherein said yeast
20 cells are cultured on a medium comprising at least one carbon substrate.

15. A method as defined in clause 14, wherein said carbon substrate is glucose, xylose, arabinose, or galactose.

16. A method as defined in clause 13, wherein said yeast
25 cells produce a supernatant concentration of at least 5 g/L 3-HP.

17. A method as defined in clause 13, wherein said yeast cells produce a supernatant concentration of at least 6 g/L 3-HP.

18. A method as defined in clause 13, wherein said yeast
5 cells produce a supernatant concentration of at least 7 g/L 3-HP.

19. A method as defined in clause 13, wherein said yeast cells produce a supernatant concentration of at least 8 g/L 3-HP.

10 20. A method as defined in clause 13, wherein said yeast cells produce a supernatant concentration of at least 9 g/L 3-HP. n

21. A method as defined in clause 13, wherein said method further comprises isolating 3-HP produced by said yeast
15 cells.

CLAIMS

1. A yeast cell for use in producing 3-hydroxypropionic acid (3-HP), wherein said yeast cell incorporates
5 genetic modification such that said cell expresses the enzymes:

- Pyruvate decarboxylase (PDC)

- Aldehyde dehydrogenase (ALD)

- Acetyl-CoA synthase (ACS)

10 - Acetyl-CoA carboxylase (ACC*) mutated in at least one dephosphorylation site to prevent inactivation by Snf1

- Malonyl-CoA reductase (MCR),

and has a reduced level of activity of NAD dependent glyceraldehyde-3-phosphate dehydrogenase (GAPDH) by virtue of
15 deletion, attenuation, disruption, down-regulation, or mutation of one or more genes expressing NAD dependent GAPDH and has at least one exogenous gene encoding NADP dependent GAPDH and/or has up-regulation of at least one endogenous gene expressing NADP dependent GAPDH, and

20 wherein combined expression of the enzymes NADP dependent GAPDH, PDC, ALD, ACS, ACC* and MCR in said host cell increases metabolic flux towards 3-HP via malonyl-CoA compared to an otherwise similar yeast cell lacking said genetic modification.

25 2. A yeast cell as claimed in claim 1, comprising one or more exogenous nucleic acid molecules encoding at least one of PDC, ALD, ACS, ACC* and/or MCR.

3. A yeast cell as claimed in claim 2, wherein a said nucleic acid molecule is expressed from multiple integrations
30 of said nucleic acid molecule in the host cell genome.

4. A yeast cell as claimed in claim 2, wherein a nucleic acid molecule encoding PDC is derived from *Saccharomyces cerevisiae*.

5. A yeast cell as claimed in claim 2, wherein the nucleic acid molecule encoding ALD is derived from *Saccharomyces cerevisiae*.

6. A yeast cell as claimed in claim 2, wherein a nucleic acid molecule encoding ACS is derived from *Salmonella enterica*.

10 7. A yeast cell as claimed in claim 2, wherein a ACC* enzyme is mutated in at least two dephosphorylation positions in the enzyme.

8. A yeast cell as claimed in claim 7, wherein the ACC* enzyme is mutated at amino acid positions Ser659 and Ser1157, wherein Ser659 and Ser1157 are replaced by amino acids comprising side chains which are incapable of being phosphorylated.

9. A yeast cell as claimed in claim 8, wherein the nucleic acid molecule encoding the non-mutated version of the ACC* enzyme is derived from *Saccharomyces cerevisiae*.

10. A yeast cell as claimed in claim 2, wherein a nucleic acid molecule encoding MCR is derived from *Chloroflexus aurantiacus*.

11. A yeast cell as claimed in claim 1, wherein a nucleic acid molecule encoding NADP dependent GAPDH is derived from *Clostridium acetobutylicum*, *Kluyveromyces lactis* or *Bacillus subtilis*.

12. A method for producing 3-HP, said method comprising culturing yeast cells as claimed in any of the preceding claims under conditions such that 3-HP is produced.

13. A method as claimed in claim 13, wherein said yeast
5 cells are cultured on a medium comprising at least one carbon substrate.


14. A method as claimed in claim 13, wherein said yeast cells produce a supernatant concentration of at least 5 g/L 3-HP.

10 15. A method as claimed in claim 13, wherein said method further comprises isolating 3-HP produced by said yeast cells.

15

1/8

Figure 1.



2/8

Figure 2.





Figure 3.



4/8

Figure 4.




Figure 5.




Figure 6.




Figure 7.





Figure 8.



INTERNATIONAL SEARCH REPORT

International application No

PCT/EP2014/062246

A. CLASSIFICATION OF SUBJECT MATTER		
INV. C12N9/02	C12N9/00	C12P7/42 C12P7/52
ADD.		
According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED		
Minimum documentation searched (classification system followed by classification symbols)		
C12N C12P		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched		
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)		
EPO-Internal, BIOSIS, EMBASE, WPI Data		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 02/42418 A2 (CARGILL INC [US]; GOKARN RAVI R [US]; SELIFONOVA OLGA V [US]; JESSEN H) 30 May 2002 (2002-05-30) the whole document	1-15
Y	WO 2012/017083 A1 (NIELSEN JENS [SE]; SHI SHUOBO [SE]) 9 February 2012 (2012-02-09) the whole document	1-15
Y	US 2013/066035 A1 (BURGARD ANTHONY P [US] ET AL) 14 March 2013 (2013-03-14) the whole document	1-15
Y	WO 2008/028002 A1 (RICE UNIVERSITY [US]; SAN KA-YIU [US]; BENNETT GEORGE [US]; LIN HENRY) 6 March 2008 (2008-03-06) the whole document	1-15
	----- -/-	
<input checked="" type="checkbox"/> Further documents are listed in the continuation of Box C. <input checked="" type="checkbox"/> See patent family annex.		
* Special categories of cited documents :		
"A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier application or patent but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed		"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "&" document member of the same patent family
Date of the actual completion of the international search		Date of mailing of the international search report
16 July 2014		11/08/2014
Name and mailing address of the ISA/ European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Fax: (+31-70) 340-3016		Authorized officer Roscoe, Richard

INTERNATIONAL SEARCH REPORT

International application No

PCT/EP2014/062246

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US 2012/135481 A1 (JESSEN HOLLY [US] ET AL) 31 May 2012 (2012-05-31) the whole document -----	1-15
A	CHELLADURAI RATHNASINGH ET AL: "Production of 3-hydroxypropionic acid via malonyl-CoA pathway using recombinant Escherichia coli strains", JOURNAL OF BIOTECHNOLOGY, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL , vol. 157, no. 4 20 February 2012 (2012-02-20), pages 633-640, XP002706395, ISSN: 0168-1656, DOI: 10.1016/J.JBIOTEC.2011.06.008 Retrieved from the Internet: URL: http://www.sciencedirect.com/science/article/pii/S0168165611003075 [retrieved on 2011-06-23] the whole document -----	1-15
A	VERHO R ET AL: "IDENTIFICATION OF THE FIRST FUNGAL NADP-GADPH FROM KLUYVEROMYCES LACTIS", BIOCHEMISTRY, AMERICAN CHEMICAL SOCIETY, US, vol. 41, no. 46, 19 November 2002 (2002-11-19), pages 13833-13838, XP008015402, ISSN: 0006-2960, DOI: 10.1021/BI0265325 the whole document -----	1-15
A	WOODS ET AL: "Yeast SNF1 is functionally related to mammalian AMP-activated protein kinase and regulates acetyl-CoA carboxylase in vivo.", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 269, no. 30, 1 July 1994 (1994-07-01) , pages 19509-19515, XP055068978, ISSN: 0021-9258 the whole document -----	1-15

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/EP2014/062246

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 0242418	A2	30-05-2002	AR 031480 A1 24-09-2003
			AR 046846 A2 28-12-2005
			AU 1981802 A 03-06-2002
			BR 0115877 A 07-10-2003
			CA 2429039 A1 30-05-2002
			CN 1556855 A 22-12-2004
			EP 1343874 A2 17-09-2003
			JP 4490628 B2 30-06-2010
			JP 2004514431 A 20-05-2004
			MX PA03004324 A 26-01-2004
			US 2004076982 A1 22-04-2004
			US 2007184524 A1 09-08-2007
			US 2008076167 A1 27-03-2008
			US 2009053783 A1 26-02-2009
			US 2012077236 A1 29-03-2012
			US 2012244586 A1 27-09-2012
			US 2013323772 A1 05-12-2013
			US 2013323807 A1 05-12-2013
			US 2013323808 A1 05-12-2013
			WO 0242418 A2 30-05-2002
WO 2012017083	A1	09-02-2012	EP 2601292 A1 12-06-2013
			US 2013197248 A1 01-08-2013
			WO 2012017083 A1 09-02-2012
US 2013066035	A1	14-03-2013	AU 2012304428 A1 02-05-2013
			CA 2848064 A1 14-03-2013
			CN 103917651 A 09-07-2014
			EP 2753699 A1 16-07-2014
			KR 20140058691 A 14-05-2014
			US 2013066035 A1 14-03-2013
			WO 2013036764 A1 14-03-2013
WO 2008028002	A1	06-03-2008	US 2010009418 A1 14-01-2010
			WO 2008028002 A1 06-03-2008
US 2012135481	A1	31-05-2012	AU 2011336923 A1 30-05-2013
			CA 2818499 A1 07-06-2012
			CN 103502432 A 08-01-2014
			EP 2643450 A2 02-10-2013
			JP 2013542747 A 28-11-2013
			KR 20130119945 A 01-11-2013
			US 2012135481 A1 31-05-2012
			US 2014065681 A1 06-03-2014
			WO 2012074818 A2 07-06-2012